Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors [Phase I and Clinical Pharmacology]

Conclusion JNJ-42756493 administered at 10 mg on a 7-days-on/7-days-off schedule achieved exposures at which clinical responses were observed, demonstrated pharmacodynamic biomarker activity, and had a manageable safety profile.

http://jco.ascopubs.org/cgi/content/short/33/30/3401?rss=1

Source: Journal of Clinical Oncology - October 16, 2015 Category: Cancer & Oncology Authors: Tabernero, Bahleda, Dienstmann, Infante, Mita, Italiano, Calvo, Moreno, Adamo, Gazzah, Zhong, Platero, Smit, Stuyckens, Chatterjee-Kishore, Rodon, Peddareddigari, Luo, Soria Tags: Phase I and Clinical Pharmacology Source Type: research